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Diarrhea induced by high doses of
nicotinamide in dialysis patients
Kidney International (2006) 69, 1914. doi:10.1038/sj.ki.5000381
To the Editor: Takahashi et al.1 have recently described the
effect of nicotinamide for controlling hyperphosphatemia in
dialysis patients. However, Rottembourg et al.2 reported
thrombocytopenia in the same setting. We have started a
prospective, open-label trial to study the efficiency and safety
of nicotinamide in our hemodialysis patients with resistant
hyperphosphatemia. Unlike Takahashi, we did not stop other
phosphate binders. Six patients have already been included.
Two patients were intolerant to sevelamer and thus only
treated with calcium carbonate. The other four patients
received a combined therapy. Five patients developed
diarrhea during the study. In two of them, it was so
important that nicotinamide had to be stopped. After
discontinuing nicotinamide, diarrhea disappeared. In the
three other patients, diarrhea improved with decreasing the
dose of nicotinamide. The diarrhea started at a mean dose of
10507447 mg. We observed a significant decrease in phosphat-
emia while on treatment (from 8578.7 to 54712.1 mg/l;
P¼ 0.0048 for the repeated measure analysis of variance),
but no effect on platelet count (from 260.167740.435
to 281.167751.503; P¼ 0.33).
Diarrhea induced by high doses of nicotinamide
is not described in non-renal failure population.3 However,
in Takahashi’s study, 7.8% of the patients developed such
an adverse effect.1 In our population, diarrhea induced
by nicotinamide might also be related to the simultaneous
use of calcium carbonate and/or sevelamer. If nicotinamide
proves to be useful in the management of hyperpho-
sphatemia, more studies are needed to evaluate its safety at
high doses.
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Tamm–Horsfall protein knockout
mice do not develop medullary
cystic kidney disease
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To the Editor: Medullary cystic kidney disease type 2
(MCKD2) and familial juvenile hyperuricemic nephropathy
(FJHN) are similar autosomal-dominant renal diseases with
shared features, including polyuria, progressive renal failure,
and abnormal urate handling, which leads to hyperuricemia
and gout. Both diseases are associated with corticomedullary
cysts, interstitial fibrosis secondary to infiltration by inflam-
matory cells, and marked thickening of tubular basement
membranes.1 Recent genetic studies in humans have shown
mutations in the UMOD (uromodulin, Tamm–Horsfall,
THP) gene in patients with MCKD2 and FJHN.2 It has been
suggested that MCKD2 and FJHN might represent different
forms of the same disease. Patients with the MCKD/FJHN
complex have also been shown to have reduced excretion of
THP in urine.3 It has remained unclear if changes of MCKD/
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Figure 1 | Renal Histology. (a and b) Kidney sections from THPþ /þ
and THP/ mice stained with hematoxylin and eosin, (c and d)
periodic acid schiff , and with (e and f) Masson’s trichrome (original
magnification  100). Renal histology was normal in all mice. There
were no areas of fibrosis or cystic change in the renal cortex or
medulla from either group of mice.
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FJHN are caused by lack of normal THP or by the presence of
abnormal THP.
We are one of two groups to generate THP-deficient
(THP/) mice by the technique of homologous recombina-
tion.4 In this study, we investigated if absence of THP in mice
leads to findings similar to those associated with human
mutations of THP. We selected age- and gender-matched
THP/ (n¼ 10) and THPþ /þ (n¼ 10) mice, and allowed
them to receive normal food and drink for 3 years. The mice
were assessed for weight, feeding behavior, and physical
activity. Mice were killed using carbon dioxide narcosis and
dissected. All visceral organs were examined for gross
pathology, and kidneys were processed for histology. The
kidney sections were stained with hematoxylin and eosin,
periodic acid schiff, and Masson’s trichrome stains. A renal
pathologist examined the slides in a blinded manner.
Results showed that there was no difference between the
groups (THP/ and THPþ /þ mice) in their level of
physical activity, weight gain, growth, and general health.
Renal histology was normal in all mice. There were no areas
of fibrosis or cystic change in the cortex or medulla in kidney
sections from either group of mice (Figure 1).
Our results demonstrate that the mere absence of THP is
not sufficient to cause histological changes associated with
MCKD2/FJHN in mice up to 3 years of age.
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Vascular injury mediated
by calcineurin inhibitors:
Contribution of rheological
factors?
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To the Editor: In a recent Nephrology Forum, an interesting
survey of endothelial dysfunction mediated by calcineurin
inhibitors and the cellular mechanisms leading to it is given
by Lamas.1 This dysfunction leads to an increased vascular
resistance and hypertension. However, an unmentioned
factor could also contribute to this endothelial dysfunction.
Changes in blood rheology can directly influence the forces
on the vessel wall. Shear stresses can influence endothelial cell
morphology and function. A decreased erythrocyte deform-
ability has been found in patients using cyclosporin, as well as
a higher plasma viscosity, fibrinogen level, and erythrocyte
aggregation.2,3 These rheological disturbances could con-
tribute to endothelial dysfunction: on the other hand, it
could also be suggested that disturbances of the endothelium
could contribute to rheological alterations. The endothelium
and blood could have an interesting interplay in this
respect.
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Steroid resistance in childhood
nephrotic syndrome
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To the Editor: We read with interest the recent article
in Kidney International by Kim et al.1 concerning childhood
nephrotic syndrome. We would like to bring to
their attention our report from nearly 20 years ago
of a cohort of 60 children with initially steroid-responsive
nephritic.2 Forty-nine (82%) had a frequently relapsing or
steroid-dependent course. Twenty of these children were
treated with cyclophosphamide owing to unacceptable
steroid toxicity; all achieved a complete remission that was
sustained in 70% of the children over a mean of 9 years of
additional follow-up, whereas 30% had one or more
subsequent relapse. Of the 29 children not treated with
cyclophosphamide, 52% continued to relapse, whereas 48%
went into a remission that was sustained for between 3 and
16 years, despite the earlier frequently relapsing/steroid-
dependent course. All 20 of the cyclophosphamide-treated
children had kidney biopsies: 10 had minimal change disease;
of these, nine had a permanent remission induced. Six had
focal sclerosis and four had mesangial proliferation; of these,
only five had permanent remission. None of the 60 children
developed renal insufficiency or hypertension. Siegel et al.3
had also earlier reported the frequent occurrence of focal
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